We have constructed an overexpression system in which the gene encoding the B subunit of cholera toxin (CTB) was placed under the control of the strong tacP promoter in a wide host range plasmid. Recombinant nontoxigenic classical and El Tor Vibrio cholerae strains of different serotypes harboring this plasmid excreted 10-to 100-fold higher amounts of CTB than any other wild-type or recombinant strain tested and may therefore be useful killed oral vaccine strains. The manipulations to place the CTB gene under tacP also included, by design, the introduction of single enzyme restriction sites for gene fusions to the CTB amino terminus. Cloning into these sites allows construction of CTB-derived hybrid proteins carrying various putative vaccine peptide antigens.
Cholera and diarrhea caused by enterotoxigenic Escherichia coli are important causes of morbidity and mortality in many developing countries. Vibrio cholerae of serogroup 01 and enterotoxigenic E. coli may induce diarrhea when multiplying in the gut of infected individuals by releasing cholera toxin (CT) or heat-labile enterotoxin (LT), respectively. These toxins are very similar structurally and functionally and are composed of two types of subunits, a single copy of A (CTA or LTA), which is responsible for activation of the adenylate cyclase in the intestinal cell of the host, and a pentamer of B (CTB or LTB), which binds the respective holotoxin to its intestinal receptor (1, 2) .
CTB is an effective oral immunizing agent, which in a large field trial has been shown to afford protection against both cholera and enterotoxigenic E. coli-caused diarrhea. This has made CTB as such an important component, together with killed whole vibrios, of an oral cholera vaccine (3, 4) . Moreover, CTB has attracted much interest recently as an immunogenic carrier for various other peptide or carbohydrate antigens (5, 6) and has also been used as a receptorblocking and receptor-modulating agent for short term prophylaxis of cholera and enterotoxigenic E. coli diarrhea (7, 8) . These findings have now emphasized the need to increase the yields of CTB for large-scale production, ideally avoiding at the same time the drawback in currently used preparation methods of having to purify the CTB protein from active toxin. To facilitate vaccine development based on use of CTB, we have constructed an overexpression system in which the CTB gene is under the control of the strong tacP promoter in a wide host range plasmid. Recombinant V. cholerae of different biotypes and serotypes carrying this plasmid produced increased amounts of CTB, which was secreted to the cell culture medium. Overexpression of CTB may now aid its purification by simplified means and assist in preparing improved killed oral cholera vaccine strains. In addition, the overexpression system developed allows for gene fusions at the CTB amino terminus, facilitating the construction of peptide-bearing immunogenic hybrid proteins.
MATERIALS AND METHODS
Gene Fusions and DNA Sequencing. The unphosphorylated oligodeoxynucleotides used to join the Sac 1 3' end of the LTB leader to the 5' Nde I of CTB were purchased as single strands from the Department of Immunology, Biomedical Centre, University of Uppsala. After pairing, the oligonucleotides had Sac I and Nde I compatible single-stranded extensions and could be joined directly to Sac 1/HindIII restricted pMMB68 (9, 10) . Ligation was performed overnight at 40C with T4 ligase and with a 10-fold molar excess of oligonucleotide to plasmid. To the ligation mixture a purified Nde I/H ndIII fragment from plasmid pCVD30 containing the CTB gene (11) was added in equimolar amounts with respect to vector plasmid and the ligase reaction continued at 4°C for 18 hr. The ligated DNA was subsequently transformed into competent E. coli HB101 cells with selection for ampicillin resistance (100 ,ug/ml). To verify that the predicted sequences had been generated after cloning, the hybrid gene was subcloned into M13 and sequenced by the dideoxynucleotide method (12) .
Transfer of Plasmids to V. cholerae and Induction by Isopropyl f8-D-Thiogalactopyranoside (IPTG). Plasmid pJS162 containing the CTB gene under the control of tacP ( Fig. 1 ) was transferred by conjugation from a helper E. coli strain (13) to the El Tor V. cholerae 01 JBK70 (14) , using polymyxin B (50 units/ml) and ampicillin (100 ,ug/ml) for counterselection of the donor. When the plasmid was transferred to classical strains, rifampicin derivatives of them were first isolated. Selection for the recipient vibrio strains in this instance was done with rifampicin (50 ,g/ml) and ampicillin (100 ,ug/ml). For induction with IPTG, cultures were grown at 37°C to the desired optical density (A6w) in LB broth supplemented with antibiotics and then IPTG was added to the final concentrations needed. Growth was continued for 4 hr and the cells and culture supernatants were separated by centrifugation. Cell pellets were gently washed and resuspended in 1 original vol of cold phosphate buffered saline (pH 7.2) to be broken by two 30-sec sonic bursts with a miniprobe (Branson Sonifier).
Immunoassay of CTB. Detection of recombinant CTB was carried out by the monosialoganglioside (GM1) ELISA (15) using anti-CTB monoclonal antibodies, which do not crossreact with LTB (16) . Samples tested were either culture supernatants or sonicated cell pellets. Quantitation of recombinant CTB was made against a standard curve established for concurrently tested purified CTB from strain 569B (kindly provided by Institut Merieux, Lyon, France).
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Biochemistry: Sanchez and Holmgren Purification of CTB and Amino Terminus Determination. The recombinant CTB was purified from a culture supernatant of JBK70 carrying plasmid pJS162 by affinity chromatography on a lyso-GM1 ganglioside Spherosil column (17) . Purified CTB was subjected to determination ofthe amino-terminal residue as described by Von Bahr-Lindstrom et al. (18) . NaDodSO4/PAGE. Purified recombinant CTB was electrophoresed in NaDodSO4/13.5% polyacrylamide slab gels and the proteins were stained with Coomassie blue. To test for association of CTB into oligomers, samples were treated just prior to electrophoresis with 0.1% NaDodSO4 sample buffer for 5 min at room temperature or subjected to boiling.
Association with CTA in Vitro. Purified CTA (prepared from 569B CT; List Biological Laboratories, Campbell, CA) was mixed with purified recombinant or 569B CTB to give a total protein concentration of 200 pug/ml (19) and in the molar CTB/CTA ratio normally found in intact CT. After mixing, samples were acidified with 0.2 M glycine buffer (pH 2.7) and then neutralized by dialysis overnight against several changes of 0.05 M Tris buffer (pH 8.0). The neutralized samples were then tested with subunit-specific monoclonal antibodies by GM1 ELISA. The amounts of 569B CTA that associated with recombinant or 569B CTB to give holotoxin were calculated using untreated homologous CT as a reference.
Immunization of Rabbits and Serological Methods. Adult rabbits were immunized subcutaneously with 30 pug of the recombinant CTB or 569B CTB biweekly, using complete Freund's adjuvant for the first inoculation and then incomplete adjuvant. After the third immunization, the animals were bled and serum was collected for analysis.
Double diffusion in gel immunoprecipitation analysis ad modum Ouchterlony was performed using the microchamber system described by Wadsworth (20) .
Titration of anti-toxin antibodies was performed by GM1 ELISA (15) using purified recombinant and 569B CTB as antigens attached to GM1-coated plates. Neutralizing antibodies were assayed by the skin test method of Craig (21) using purified 569B CT as test toxin. Heat-inactivated serum was mixed in serial dilutions with equal volumes of purified 569B CT (40 ng/ml in physiological phosphate buffer supplemented with 10 mg of bovine serum albumin per ml), and 0.1 ml of the mixture was then tested for residual toxicity by intradermal injection.
RESULTS
Placement of the CTB Gene Under tacP. The DNA encoding the LTB leader has a single EcoRI restriction site at its 5' end located just upstream of the ribosome binding site that was used to insert the LTB gene after the tacP promoter (10). To profit from this strategically located EcoRI site (which is missing in the CTB gene) for expression of CTB from the same promoter, we fused genetically the mature CTB protein to the leader peptide of LTB in pMMB68. The CTB gene from pCVD30 (originating from V. cholerae strain 0395, classical Ogawa) has an Nde I site at the position for amino acid (aa) 18 of the leader peptide, while the LTB gene has a Sac I recognition sequence at the beginning of the mature protein.
Fusion of the CTB gene by its 5' Nde I end to the 3' Sac I end in the LTB gene, via an ad hoc synthetic linker (Fig. 1A) , leads to substitution of the CTB leader peptide by that in LTB. The resulting pJS162 plasmid (Fig. 1B) contained the hybrid CTB gene as an EcoRI/HindIII downstream of the tacP promoter.
Analysis of the CTB Gene Sequence. Sequencing of the hybrid CTB gene in plasmid pJS162 confirmed the sequence reported for the LTB leader portion (22) and showed a high degree ofoverall homology with previously reported El Tor and classical CTB mature sequences (23) (24) (25) . A comparison between our recombinant CTB (from a V. cholerae 0395 classical strain) and those other sequences is presented in Fig. 2 . Expression of CTB from tacP in V. cholerae. Conjugal transfer of pJS162 to the toxin-deleted JBK70 V. cholerae strains followed by induction with IPTG led to production of 40-50 ,tg of CTB per ml, of which >95% was secreted into the culture medium (Fig. 3) . Expression of CTB to levels up to 50-100 Ag/ml was also achieved in several toxin-or CTA-deleted classical and El Tor strains (Table 1) . This represented a marked overexpression of CTB in comparison with the levels produced by many wild-type or recombinant V. cholerae strains examined, including the hypertoxigenic 569B strain that is currently used for purification of CTB for vaccine production. The recombinant CTB could then readily be purified in high yield from the culture supernatants of either of these strains using receptor-specific affinity chromatography on lyso-GM1 ganglioside (17) .
Characterization of Recombinant CTB Protein. (i) Amino terminus determinations. Cleavage of the precursor peptide of the recombinant CTB would have been naturally predicted to take place at either one or both of the original leader peptidase recognition sites in LTB or CTB. Identification of the first amino acid in the purified protein gave both tyrosine and alanine residues. This and the fact that the recombinant CTB was slightly larger than native CTB as determined by NaDodSO4/PAGE (Fig. 4) suggested that proteolytic processing of the leader peptide had taken place between the glycine encoded by the linker (position -5) and tyrosine (position -4) as well as between this latter amino acid and alanine at -3 (Fig. 2) . When the remainder of the treated CTB was subjected again to amino terminus determination alanine and histidine residues were now identified, confirming the (26, 27) , which disagree with those predicted by our CTB DNA sequence, are in parentheses, residues in the CTB from El Tor strains (23) (24) (25) , which differ from ours and those in classical 569B CTB, are in parentheses and in boldface type. postulated cleavage positions and providing evidence that the recombinant CTB carried short peptide extensions at its amino terminus consisting of either 3 or 4 amino acids.
(ii) Receptor and CTA subunit recognition. The presence of the few extra amino acids in the CTB did not affect its recognition of the GM1 receptor. The binding affinity for plastic-coated GM1 ganglioside was compared for the recombinant CTB and 569B CTB using the GM1 ELISA and no difference was revealed (data not shown). Retention of high binding affinity for GM1 ganglioside was in fact also taken advantage of in the purification of CTB as described above.
The recombinant CTB was also unaffected in its ability to both oligomerize and associate with CTA, as shown by the high percentages of holotoxin recovered after acidification and neutralization of the mixed subunits (Table 2) .
(iii) Immunological properties of recombinant CTB. To determine whether the extra amino acids in CTB affected its immunoreactivity or even resulted in the appearance of new epitopes, we prepared rabbit antisera against recombinant and 569B CTB. The anti-CTB titers in GM1 ELISA were similar (range, 4 x 105 to 1 x 106) for anti-recombinant and
anti-569B CTB as tested with either of the two CTB preparations as solid-phase antigen. Likewise, the neutralizing antitoxin titers did not differ, the sera against either recombinant or 569B CTB being able to completely neutralize 2 ng of CT at a concentration of 1 x 10-4. Ouchterlony immunodiffusion tests performed with the purified recombinant CTB or 569B CTB and their corresponding rabbit immune sera as reactants showed immunoprecipitation bands of coalescence without any "spurs," indicating complete "identity" between the recombinant and native CTB (Fig. 5 ). (569B derivative) CTA-CTB+ All strains were grown for the same periods at 30'C. Strains carrying pJS162 were grown to A600 = 1.0 before addition of IPTG to 100 ug/ml, after which incubation was continued for 4 hr. Strains JS1569 and JS1395 are rifampicin-resistance derivatives from strain CVD103 and CVD101 (11) (0395 CTA-derivative), respectively. The levels of CTB produced by these latter strains in the absence of IPTG were <0.5 ,tg/ml and therefore did not contribute significantly to the values in the presence of the inducer. *Nonfunctional (CTA-) or functional (CTA+) CTA gene and/or nonfunctional (CTB-) or functional (CTB+) CTB gene. Strains were prepared by gene deletion (11) . DISCUSSION The demonstration that oral immunization with CTB provides protection against cholera and enterotoxigenic E. coli diarrhea in humans (3, 4) and the evidence in experimental systems that CTB is also an effective immunogenic carrier for various other peptide or carbohydrate vaccine candidate antigens (5, 6) 4) were electrophoresed in a NaDodSO4/ 13.5% polyacrylamide gel after treatment in sample buffer for 5 min at 100°C (lanes 1 and 3) or at room temperature (lanes 2 and 4) . A molecular mass marker (Bio-Rad) with the approximate sizes of protein standards (kDa) is shown (lane MW). The slower migration of the recombinant CTB as compared to the 569B CTB is only slightly noticeable when examined as the monomers (Bin) but is more obvious in the oligomeric (pentameric) forms (Bp). 109.6 (82%) The affinity of recombinant or 569B CTB for CTA was tested by their ability to associate in vitro to form cholera holotoxin. Mixtures of CTA and CTB in a 1:5 molar ratio were acidified to pH 2.7 to dissociate the CTB pentamers (19) . Association between CTA and the added CTB was subsequently favored by neutralization of the solution by dialysis against Tris (pH 8.0). Neutralized samples were assayed directly by GM1 ELISA with CTA-and CTB-specific monoclonal antibodies. Values in parentheses refer to the fraction of the subunit found as CT calculated with relation to the maximum amount theoretically able to form holotoxin. achieved overexpression of CTB by placing the CTB structural gene under the control of the strong tacP promoter. Various V. cholerae strains harboring the wide host range plasmid (pJS162) containing the tacP-directed CTB overexpression system expressed 10-to 100-fold higher levels of CTB than any other wild-type or recombinant strains tested.
The reason for the efficient expression of CTB attained by us in contrast with previous attempts using the same promoter (25) has not been established. The removal of the CTB DNA upstream of the Nde I site used for cloning may have eliminated sequences interfering with high expression by affecting transcription (28) or translation (29) . A positive effect on translation by the LTB ribosome binding site (Shine-Dalgarno sequence) seems unlikely since its complementarity to the 16S rRNA 3' end is less than that of the original CTB Shine-Dalgarno sequence (23) . Although high expression of CTB in V. cholerae has been considered possible only when directed from the original ctx promoter and in the presence of ancillary regulatory elements (25) Proc. Natl. Acad. Sci. USA 86 (1989) been described (26, 27) . Among the four (24) or five (25) (33, 34) . To create the possibility of obtaining CTB-derived hybrid proteins by gene fusion as an extra bonus of the tacP-directed overexpression system, we arranged the constructions so as to have adjacent single Sac I and Sma I recognition sequences at the amino terminus of the CTB gene. Use of these restriction sites allows linkage of diverse peptide antigens to CTB for immunoprotection studies against, e.g., viral, bacterial, and parasitic diseases. The accessibility of this approach has recently been demonstrated by the fusion and expression of a synthetic DNA sequence encoding a nontoxic decapeptide antigen, derived from the E. coli heat-stable enterotoxin, to the pJS162 CTB gene (35) .
